AmStem Announces Positive Results From Consumer SteMixx(TM) Study

SAN FRANCISCO, CA--(Marketwire - August 09, 2010) -

Highlighted Links

MacReport Media Publishing

AmStem Corporation

AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today highly positive final results from its preliminary consumer study of SteMixx™, a new facial skin care product derived from secreted stem cell proteins and other natural ingredients.

David Stark, President of AmStem International, Inc. said, "The responses from the trial have exceeded our expectations and thrilled everyone associated with this product, showing that 100% of our consumer testers are happy with SteMixx™. All of the testers responded to our surveys, which is quite unusual, and over 95% of them reported some sort of positive result using SteMixx for just 10 days."

The instructions for the consumer study were to use the five specially designed applicators for two days each, then "rest" the skin for three weeks before filling out the final survey. The 21 testers were instructed not to use any other skin care products (except cleanser and sunscreen) for the full month. Those with recent facial procedures such as a light or deep peel, dermabrasions, or injections were excluded from the study.

Stark said, "This clearly demonstrates that SteMixx™ will have an enthusiastic following when we leverage these results into a full-blown marketing campaign. The testers were very specific about improvements in their overall youthful appearance, with over 80% reporting noticeable reductions in the appearance of blemishes, discoloration, fine lines and wrinkles. Unexpectedly, one woman reported positive results using the product on her hands, which was not meant to be part of the study, but provided an encouraging insight into the versatility of SteMixx™."

Some samples of comments made by participants (reprinted by permission):

• "People think I look much younger."
• "It did a great job evening out my skin tone. My skin looked very healthy."
• "I used it on my dry and sun damaged hands here in Arizona. It smoothed out my skin and made it baby soft and faded my sunspots. My hands look 10 years younger."
• "Great results. Received a lot of compliments on my skin."
• "I like it a lot. My skin is much much smoother and finely grained. The bumps from little cysts are gone."
• "My skin looks great . I do look younger."
• "Normally my skin is very dry and flaky when I don't use moisturizer. I noticed with this product, I didn't have that problem."

Based on these early positive results, AmStem confirmed it has engaged a labeling consultant for the flagship SteMixx™ product, with the intention of making it available for retail consumer use in the U.S. as soon as possible. The Company is seeking an advantageous and regulatory-compliant niche in the estimated $21 billion U.S. cosmetics market.

AmStem is already planning the first formal clinical trial of SteMixx™ in the United States.

Stark said, "This study will help decide what claims we will make in our labeling and advertising of SteMixx™. The principal investigator will be Dr. Shelly Friedman of the Scottsdale Institute for Cosmetic Dermatology. The study is expected to begin enrollment this month immediately following approval from an Institutional Review Board (IRB).

SteMixx™, along with an extensive line of cosmeceutical and hair restoration products, was developed by Dr. Han Hoon, CEO of Histostem, Ltd., in Seoul, Korea. Histostem is a 90% owned subsidiary of AmStem Corporation. Histostem operates one of the largest cord blood banks in the world with over 80,000 units stored for personal and unrelated transplant uses.

SteMixx™ has been approved by the Korean FDA as a "functional cream" for the treatment of facial skin disfiguration associated with signs of aging such as wrinkles. AmStem's professional studies are for the purpose of validating these claims, which have not yet been reviewed by the U.S. FDA.

About AmStem, Inc.
AmStem, Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.

An investment profile on AmStem may be found at http://www.hawkassociates.com/profile/amst.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

For more information contact AmStem CFO Andrew Norstrud at (813) 283-2556 or Tom Fox at Hawk Associates at (305) 451-1888 or visit: http://amsteminc.com.

Forward-Looking Statements
Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.